SiBone (NASDAQ:SIBN) Insider Sells $84,105.00 in Stock

November 3, 2026 by InsiderTrades.com

Key Points

SVP Michael Pisetsky sold 29,665 SiBone shares for approximately $655,893, reducing his ownership by 15.28% to 164,444 shares.
SiBone’s latest quarterly results exceeded expectations, with a loss of $0.08 per share versus the anticipated $0.13 loss and revenue of $55.7 million, slightly above estimates.
The company remains unprofitable but reported improving cash flow and operating performance; analysts maintain a “Moderate Buy” consensus with an average price target of $24.50.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 3,738 shares of the stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00. Following the completion of the transaction, the insider directly owned 214,497 shares of the company's stock, valued at approximately $4,826,182.50. The trade was a 1.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

4 Recent Earnings Winners Riding Fresh Momentum in May

Anshul Maheshwari also recently made the following trade(s):

On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total value of $60,321.24.
On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total value of $233,999.96.
On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total value of $112,353.85.
On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Stock Performance

NASDAQ:SIBN opened at $20.22 on Tuesday. The stock's fifty day moving average is $19.42 and its 200 day moving average is $16.45. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $22.95. The firm has a market capitalization of $896.76 million, a PE ratio of -59.47 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The company had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, sell-side analysts anticipate that SiBone will post -0.40 earnings per share for the current year.

Wall Street Analyst Weigh In

SIBN has been the subject of several analyst reports. TD Cowen raised their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Truist Financial upped their price target on shares of SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, October 14th. UBS Group increased their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.50.

Get Our Latest Stock Report on SiBone

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SIBN. Versant Capital Management Inc raised its stake in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. State of Wyoming boosted its holdings in shares of SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company's stock valued at $137,000 after purchasing an additional 4,490 shares during the period. Inceptionr LLC bought a new position in SiBone in the first quarter worth approximately $156,000. ADAR1 Capital Management LLC bought a new position in SiBone in the first quarter worth approximately $159,000. Finally, Elevation Point Wealth Partners LLC bought a new position in SiBone in the first quarter worth approximately $204,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone News Roundup

Here are the key news stories impacting SiBone this week:

Positive Sentiment: Quarterly results beat expectations. SI-BONE reported a third-quarter loss of $0.08 per share, better than the $0.13 loss analysts expected. Revenue rose 14.5% year over year to $55.7 million, narrowly exceeding the $55.31 million consensus estimate. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
Positive Sentiment: Profitability and cash flow improved. Adjusted EBITDA increased 32.4% to $3.0 million, while operating cash flow reached $5.9 million, up 154.4% from the prior-year period. SI-BONE ended the quarter with $146.3 million in cash and equivalents, supporting continued investment in growth. SI-BONE Reports Third-Quarter 2026 Results
Positive Sentiment: Procedure growth and product catalysts remain favorable. U.S. procedure volume grew approximately 20%, the active U.S. physician base expanded 16% to 1,770, and the company reaffirmed its 2026 revenue guidance. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to $50,000 per qualifying procedure may support future adoption. SI-BONE Reports Third-Quarter 2026 Results
Neutral Sentiment: The company remains unprofitable. SI-BONE posted a $3.6 million net loss, despite improving 20.7% year over year. Its negative net margin and return on equity indicate that the business has not yet reached sustained GAAP profitability.
Negative Sentiment: Two insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for approximately $655,893, reducing his holdings by 15.28%. Insider Anshul Maheshwari sold 3,738 shares for about $84,105. Although both executives retained substantial positions, the sales could create modest sentiment pressure, particularly with the stock trading near its 52-week high. Insider Sale Filing

SiBone Company Profile

(Get Free Report)

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.